Table 3.
Baseline Characteristics of Patients with Progressive Disease
| Characteristics | Continue sintilimab group (n = 47) |
Discontinue sintilimab group (n = 35) |
P value |
|---|---|---|---|
| Age (year) | 0.402 | ||
| < 65 | 36 (76.6) | 30 (85.7) | |
| ≥ 65 | 11 (23.4) | 5 (14.3) | |
| Gender | 1.000 | ||
| Female | 6 (12.8) | 4 (11.4) | |
| Male | 41 (87.2) | 31 (88.6) | |
| HBsAg | 0.374 | ||
| Positive | 37 (78.7) | 31 (88.6) | |
| Negative | 10 (21.3) | 4 (11.4) | |
| Liver cirrhosis | 1.000 | ||
| Yes | 23 (48.9) | 18 (51.4) | |
| No | 24 (51.1) | 17 (48.6) | |
| Maximal tumor diameter (cm) | 1.000 | ||
| < 5 | 12 (25.5) | 8 (22.9) | |
| ≥ 5 | 35 (74.5) | 27 (77.1) | |
| Tumor nodules | 0.094 | ||
| Multiple | 41 (87.2) | 25 (71.4) | |
| Single | 6 (12.8) | 10 (28.6) | |
| AFP (ng/mL) | 0.824 | ||
| < 400 | 27 (57.4) | 19 (54.3) | |
| ≥ 400 | 20 (42.6) | 16 (45.7) | |
| PIVKA-II (mAU/mL) | 0.498 | ||
| < 2050 | 27 (57.4) | 23 (65.6) | |
| ≥ 2050 | 20 (42.6) | 12 (34.3) | |
| TB (umol/L) | 0.188 | ||
| < 17.1 | 26 (55.3) | 14 (40.0) | |
| ≥ 17.1 | 21 (44.7) | 21 (60.0) | |
| Albumin (g/L) | 1.000 | ||
| < 35 | 11 (23.4) | 9 (25.7) | |
| ≥ 35 | 36 (76.6) | 26 (74.3) | |
| ALBI grade | 0.284 | ||
| 1 | 31 (66.0) | 19 (54,3) | |
| 2 | 16 (34.0) | 16 (45.7) | |
| 3 | 0 (0.0) | 0 (0.0) | |
| Prothrombin time (second) | 0.374 | ||
| >13 | 10 (21.3) | 4 (11.4) | |
| ≤ 13 | 27 (78.7) | 31 (88.6) | |
| Creatinine (umol/L) | NA | ||
| > 106 | 0 (0.0) | 0 (0.0) | |
| ≤ 106 | 47 (100.0) | 35 (100.0) | |
| Platelet (X109/L) | 0.251 | ||
| < 100 | 6 (12.8) | 8 (22.9) | |
| ≥ 100 | 41 (87.2) | 27 (77.1) | |
| Blood glucose (mmol/L) | 0.567 | ||
| < 7 | 7 (14.9) | 7 (20.0) | |
| ≥ 7 | 40 (85.1) | 28 (80.0) | |
| Extrahepatic metastases | 0.580 | ||
| Yes | 10 (21.3) | 5 (85.7) | |
| No | 37 (78.7) | 30 (14.3) | |
| Portal vein tumor thrombus | 0.418 | ||
| With | 16 (34.0) | 14 (40.0) | |
| Without | 31 (66.0) | 21 (60.0) | |
| BCLC stage | 0.969 | ||
| B | 28 (59.6) | 21 (46.7) | |
| C | 19 (40.4) | 14 (53.3) | |
| Subsequent treatment | 0.706 | ||
| Lenvatinib | 30 (63.8) | 21 (60.0) | |
| Sorafenib | 13 (29.8) | 10 (28.6) | |
| Regorafenib | 4 (8.5) | 3 (8.6) | |
| Abandonment | 0 (0.0) | 1 (2.9) |
Abbreviations: HBsAg Hepatitis B surface antigen, AFP Alpha fetoprotein, TB Total bilirubin PIVKA-II Protein induced by vitamin K absence or antagonist-II, ALBI Albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, TACE Transarterial chemoembolization